Skip to main content

Research Repository

See what's under the surface


Mirtazapine for chronic breathlessness? A review of mechanistic insights and therapeutic potential (2018)
Journal Article
Lovell, N., Wilcock, A., Bajwah, S., Etkind, S., Jolley, C., Maddocks, M., & Higginson, I. (2019). Mirtazapine for chronic breathlessness? A review of mechanistic insights and therapeutic potential. Expert Review of Respiratory Medicine, 13(2), 173-180. doi:10.1080/17476348.2019.1563486

Introduction: Chronic breathlessness is a common and distressing symptom of advanced disease with few effective treatments. Central nervous system mechanisms are important in respiratory sensation and control. Consequently, drugs which may modify pro... Read More

Upper GI biopsies for adenocarcinoma: how many biopsies should endoscopists take? (2018)
Journal Article
Kaye, P., Lindsay, D., Madhusudan, S., Vohra, R., Catton, J., Platt, C., & Ragunath, K. (2019). Upper GI biopsies for adenocarcinoma: how many biopsies should endoscopists take?. Histopathology, 74(6), 959-963. doi:10.1111/his.13816

Aims: There is evidence that 4 or 5 gastric cancer biopsies are required for accurate HER2 interpretation. However, the number of biopsies that need to be taken to reach this number of viable cancer biopsies is without evidence. This study aimed to a... Read More

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells (2018)
Journal Article
Grundy, M., Balakrishnan, S., Fox, M., Seedhouse, C., & Russell, N. (2018). Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells. Oncotarget, 9, doi:10.18632/oncotarget.26540

Acute myeloid leukaemia (AML) cells often up-regulate pro-survival members of the BCL-2 protein family, such as BCL-2 and MCL-1, to avoid apoptosis. Venetoclax (ABT-199) targets BCL-2 and has shown promising efficacy in AML but over-expression of MCL... Read More

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4 (2018)
Journal Article
Tzelepis, K., De Braekeleer, E., Aspris, D., Barbieri, I., Vijayabaskar, M. S., Liu, W., …Vassiliou, G. S. (2018). SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nature Communications, 9(1), doi:10.1038/s41467-018-07620-0

We recently identified the splicing kinase gene SRPK1 as a genetic vulnerability of acute myeloid leukemia (AML). Here, we show that genetic or pharmacological inhibition of SRPK1 leads to cell cycle arrest, leukemic cell differentiation and prolonge... Read More

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer (2018)
Journal Article
Joseph, C., Arshad, M., Kurozomi, S., Althobiti, M., Miligy, I. M., Al-Izzi, S., …Rakha, E. A. (2019). Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 174(2), 387-399. doi:10.1007/s10549-018-05085-9

Purpose CD133/ prominin 1 is a cancer stem cell marker associated with cancer progression and patient outcome in a variety of solid tumours, but its role in invasive breast cancer (BC) remains obscure. The current study aims to assess the prognostic... Read More

Connexin 43 is an independent predictor of patient outcome in breast cancer patients (2018)
Journal Article
Chasampalioti, M., Green, A. R., Ellis, I. O., Rakha, E. A., Jackson, A. M., Spendlove, I., & Ramage, J. M. (2018). Connexin 43 is an independent predictor of patient outcome in breast cancer patients. Breast Cancer Research and Treatment, doi:10.1007/s10549-018-5063-9

Purpose Gap junctions are specialized membrane structures that form channels between adjacent cells allowing cell communication. Gap junctions and specifically Connexin 43 (Cx43) are down-regulated in cancer; however, there are contrasting reports... Read More

Glutamate dehydrogenase (GLUD1) expression in breast cancer (2018)
Journal Article
Craze, M. L., El-Ansari, R., Aleskandarany, M. A., Cheng, K. W., Al-Farsi, L., Masisi, B., …Green, A. R. (2019). Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment, 174(1), 79–91

Dysregulated cellular metabolism is regarded as one of the hallmarks of cancer with some tumours utilising the glutamine metabolism pathway for their sustained proliferation and survival. Glutamate dehydrogenase (GLUD1) is a key enzyme in glutaminoly... Read More

Molecular mechanisms governing the stem cell's fate in brain cancer: factors of stemness and quiescence (2018)
Journal Article
Gulaia, V., Vadim, K., Nikita, S., Eduardas, C., Rybtsov, S., Ruzov, A., & Kagansky, A. (2018). Molecular mechanisms governing the stem cell's fate in brain cancer: factors of stemness and quiescence. Frontiers in Cellular Neuroscience, 12, doi:10.3389/fncel.2018.00388

Cellular quiescence is a reversible, non-cycling state controlled by epigenetic, transcriptional and niche-associated molecular factors. Quiescence is a condition where molecular signaling pathways maintain the poised cell-cycle state whilst enabling... Read More

Calpain system protein expression and activity in ovarian cancer (2018)
Journal Article
Zhang, S., Deen, S., Storr, S. J., Chondrou, P. S., Nicholls, H., Yao, A., …Martin, S. G. (2019). Calpain system protein expression and activity in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 145(2), 345-361. doi:10.1007/s00432-018-2794-2

Purpose: Expression of members of the calpain system are associated with clinical outcome of patients with, amongst others, breast and ovarian cancer, with calpain-2 expression in ovarian cancer being implicated in chemo-resistance and survival. This... Read More

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ (2018)
Journal Article
Toss, M. S., Miligy, I. M., Gorringe, K. L., McCaffrey, L., Alkawaz, A., Abidi, A., …Rakha, E. A. (2018). Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. Modern Pathology, 32, 639–649. doi:10.1038/s41379-018-0180-x

Legumain is a proteolytic enzyme and playing a role in the regulation of cell proliferation in invasive breast cancer. Studies evaluating its role in ductal carcinoma in situ (DCIS) are lacking. Here, we aimed to characterise legumain protein express... Read More

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS) (2018)
Journal Article
Toss, M. S., Miligy, I. M., Gorringe, K. L., Alkawaz, A., Khout, H., Ellis, I. O., …Rakha, E. (2018). Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). British Journal of Cancer, 119, 1518–1526. doi:10.1038/s41416-018-0337-x

Background: Extracellular matrix (ECM) plays a crucial role in tumour behaviour. Prolyl-4-hydroxlase-A2 (P4HA2) is a key enzyme in ECM remodelling. This study aims to evaluate the prognostic significance of P4HA2 in breast ductal carcinoma in situ (D... Read More

VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy (2018)
Journal Article
Onions, K. L., Gamez, M., Buckner, N. R., Baker, S. L., Betteridge, K. B., Desideri, S., …Foster, R. R. (2019). VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy. Diabetes, 68(1), 172-187. doi:10.2337/db18-0045

Elevated levels of vascular endothelial growth factor (VEGF) A are thought to cause glomerular endothelial cell (GEnC) dysfunction and albuminuria in diabetic nephropathy. We hypothesized that VEGFC could counteract these effects of VEGFA to protect... Read More

Isogenic pairs of hiPSC-CMs with hypertrophic cardiomyopathy/LVNC-associated ACTC1 E99K mutation unveil differential functional deficits (2018)
Journal Article
Smith, J. G., Owen, T., Bhagwan, J. R., Mosqueira, D., Scott, E., Mannhardt, I., …Denning, C. (2018). Isogenic pairs of hiPSC-CMs with hypertrophic cardiomyopathy/LVNC-associated ACTC1 E99K mutation unveil differential functional deficits. Stem Cell Reports, 11(5), 1226-1243. doi:10.1016/j.stemcr.2018.10.006

Hypertrophic cardiomyopathy (HCM) is a primary disorder of contractility in heart muscle. To gain mechanistic insight and guide pharmacological rescue, this study models HCM using isogenic pairs of hiPSC-CMs carrying the E99K-ACTC1 cardiac actin mut... Read More

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair (2018)
Journal Article
Johnston, S. J., Ahmad, D., Aleskandarany, M. A., Kurozumi, S., Nolan, C. C., Diez-Rodriguez, M., …Rakha, E. A. (2018). Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. BMC Cancer, 18, doi:10.1186/s12885-018-4924-2

Developing an integrated rehabilitation model for thoracic cancer services: views of patients, carers and clinicians (2018)
Journal Article
Bayly, J., Edwards, B. E., Peat, N., Warwick, G., Hennig, I. M., Arora, A., …Maddocks, M. (2018). Developing an integrated rehabilitation model for thoracic cancer services: views of patients, carers and clinicians. Pilot and Feasibility Studies, 4, (1-12). doi:10.1186/s40814-018-0350-0. ISSN 2055-5784

Background: Access to rehabilitation to prevent disability and optimise function is recommended for patients with cancer, including following cancer diagnosis. Models to integrate rehabilitation within oncology services as cancer treatment commences... Read More

Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer (2018)
Journal Article
Alfarsi, L. H., Elansari, R., Toss, M. S., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., …Green, A. R. (2018). Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. Breast Cancer Research and Treatment, doi:10.1007/s10549-018-4978-5

PURPOSE: Identification of effective and reliable biomarkers that could be used to predict the efficacy of endocrine therapy is of crucial importance to the management of oestrogen receptor positive (ER+) breast cancer (BC). KIF18A, a key regulator o... Read More

Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention (2018)
Journal Article
Ali, R., Al-kawaz, A., Toss, M. S., Green, A. R., Miligy, I. M., Mesquita, K. A., …Madhusudan, S. (2018). Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention. Cancer Research, doi:10.1158/0008-5472.can-18-0633

Targeting PARP1 for synthetic lethality is a new strategy for breast cancers harboring germline mutations in BRCA. However, these mutations are rare, and reactivation of BRCA-mediated pathways may result in eventual resistance to PARP1 inhibitor ther... Read More

Vestibulotoxicity associated with platinum-based chemotherapy in survivors of cancer: a scoping review (2018)
Journal Article
Prayuenyong, P., Taylor, J. A., Pearson, S. E., Gomez, R., Patel, P. M., Hall, D. A., …Baguley, D. M. (2018). Vestibulotoxicity associated with platinum-based chemotherapy in survivors of cancer: a scoping review. Frontiers in Oncology, 8, doi:10.3389/fonc.2018.00363

Background: Cochleotoxicity following the treatment with platinum-based chemotherapy is well documented. The potential for vestibulotoxicity is still unclear. This scoping review examined the extent of current research literature, summarized research... Read More

CX-4945 induces methuosis in cholangiocarcinoma cell lines by a CK2-independent mechanism (2018)
Journal Article
Lertsuwan, J., Lertsuwan, K., Sawasdichai, A., Tasnawijitwong, N., Lee, K., Kitchen, P., …Satayavivad, J. (2018). CX-4945 induces methuosis in cholangiocarcinoma cell lines by a CK2-independent mechanism. Cancers, 10(9), doi:10.3390/cancers10090283. ISSN 2072-6694

Cholangiocarcinoma is a disease with a poor prognosis and increasing incidence and hence there is a pressing unmet clinical need for new adjuvant treatments. Protein kinase CK2 (previously casein kinase II) is a ubiquitously expressed protein kinase... Read More